Y.D. More Investments Ltd Has $24.37 Million Holdings in Pfizer Inc. (NYSE:PFE)

Y.D. More Investments Ltd trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 1.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 846,615 shares of the biopharmaceutical company’s stock after selling 16,528 shares during the period. Pfizer comprises about 4.9% of Y.D. More Investments Ltd’s investment portfolio, making the stock its 3rd biggest position. Y.D. More Investments Ltd’s holdings in Pfizer were worth $24,374,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Briaud Financial Planning Inc bought a new position in shares of Pfizer during the 3rd quarter valued at approximately $30,000. GoalVest Advisory LLC boosted its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the period. Mizuho Securities Co. Ltd. bought a new position in shares of Pfizer during the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC raised its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new position in Pfizer during the 4th quarter valued at $36,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE traded up $1.56 during trading on Wednesday, reaching $27.18. The company’s stock had a trading volume of 87,843,601 shares, compared to its average volume of 42,510,742. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The firm has a market cap of $153.91 billion, a price-to-earnings ratio of 75.67, a P/E/G ratio of 1.16 and a beta of 0.61. The business’s fifty day moving average price is $26.88 and its 200-day moving average price is $28.26. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 EPS. The company’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.18%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is currently 466.67%.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent research reports. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.